A 'needle in a haystack': Drug-induced thrombotic thrombocytopenic purpura-Association or causality?
- PMID: 36661238
- DOI: 10.1111/bjh.18651
A 'needle in a haystack': Drug-induced thrombotic thrombocytopenic purpura-Association or causality?
Abstract
The risk of a drug associated with thrombotic thrombocytopenic purpura (TTP) demonstrating causality is rare, but it is important to keep an open mind of possible associations. Use of criteria to ascertain causality of drugs that may be related to thrombotic microangiopathies and exclude TTP, may be a useful resource. Commentary on: Schofield et al. Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data. Br J Haematol 2023;200:766-773.
Keywords: causality; drugs; thrombotic microangiopathy (TMA); thrombotic thrombocytopenic purpura (TTP).
© 2023 British Society for Haematology and John Wiley & Sons Ltd.
Comment on
-
Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2014 Sep 13;384(9947):1005-70. doi: 10.1016/S0140-6736(14)60844-8. Epub 2014 Jul 22. Lancet. 2014. PMID: 25059949 Free PMC article.
References
REFERENCES
-
- Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129:2836-46.
-
- George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129:886-90.
-
- Altman N, Krzywinski M. Association, correlation and causation. Nat Methods. 2015;12:899-900.
-
- MHRA. The yellow card scheme: guidance for healthcare professionals, patients and the public. 2015.
-
- WHO. The use of the WHO-UMC system for standardised case causality assessment. 2013.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources